Multivariate analysis of factors affecting overall survival, event free survival, and 60-day mortality among AML patients treated with CPX-351 or intensive chemotherapy.
Eric Jay Feldman
Research Funding - Celator
Jeffrey E. Lancet
Research Funding - Celator
Jonathan E. Kolitz
Research Funding - Celator
Donna Hogge
Research Funding - Celator
Martin S. Tallman
Research Funding - Celator
Stuart L. Goldberg
Research Funding - Celator
Tibor Kovacsovics
Research Funding - Celator
Arthur Chin Louie
Employment or Leadership Position - Celator
Stock Ownership - Celator
Jorge E. Cortes
Research Funding - Celator